As we begin to bring in this year’s harvest with our farmer partners, a regional Czech TV crew stopped by to make a report, interviewing our CEO and some of the team carrying out this tough manual labor. Our production is in cooperation with Biofarm Sasov in the middle of the Czech Highlands.
Vignesh Murthy is one of the few daring individuals who has chosen to take on the daunting task of sowing the seeds of this nascent industry (pun most certainly intended). While it’s hard to catch a hold of him (owing to his hectic travel schedule between Uttarakhand and Bangalore), we managed to conduct an interview with him via satellite, and came away inspired.
Hempoint supplied seed for the historic planting of 60 acres on the Colville Reservation in Washington (USA) that will be harvested this autumn. The crop is among the first allowed under the state of Washington’s government controlled industrial hemp research pilot program and the first on tribal lands. The lands are under the 12 Confederated (native American) Tribes of the Colville’s program to increase revenue for tribal members and create jobs to replace those of a lagging timber industry.
Hempoint for the second year is co-organizer of the international Hemp2020 Investment Summit in Poland. Hemp industry leaders from the USA and Europe will address the Summit Oct 20-21, 2017 at HempToday Center in Poland. this autumn, HempToday, co-partner and the event’s host, has announced. Speakers and attendees at this year’s edition will put a particular emphasis on expanding cooperation and business deals among firms from North America and Europe, organizers said. Only 8 signups for Hemp2020 remain available.
Europe-based cannabidiol (CBD) stakeholders have launched an information-gathering effort to bolster their arguments aimed at keeping CBD off international drug schedules. The initiative is in anticipation of a World Health Organization (WHO) expert committee meeting in November that is to review CBD and 15 other psycho-active substances. Full story on HempToday.
60th session First Intersessional Meeting
Agenda Item 1 — Thematic discussions on the implementation of the UNGASS outcome document : Chapter 5 “Operational recommendations on Cross-cutting issues in addressing and countering the world drug problem: Evolving reality, trends and existing circumstances, emerging and persistent challenges and threats, including new psychoactive substances, in conformity with the three international drug control conventions and other relevant international instruments.” Read more “Statement by NGO Konopa addressed to Commission on Narcotic Drugs”
PFC is aiming to ensure quality in the cultivation, manufacturing, distribution and laboratory supply chains; ensuring patients, doctors and governments compliance with best practices. The event is holding place our partner’s premises – Mendel University in Brno on November 15th – 17th, 2016. Deadline for registration: November 11th, 2016.
Twenty-four leading hemp professionals from all over the world gathered in Poland Friday and Saturday, Oct. 21-22, 2016 for the Hemp2020 Investment Summit. Most rolled in on Thursday for the pre-Summit reception in The Palace at Nakło — HempToday headquarters. We shared ideas and intelligence and heard the stories that only a group of hemp veterans with more than 140 years combined experience in the industry can tell — our Summit speakers.
Cannabidiol (CBD) is one of the non-psychotropic cannabinoids in industrial hemp. The last couple of years have seen growing interest in CBD. Cannabidiol not only has a plethora of beneficial health effects, but it also has no relevant side-effects, even when it is administered at high doses. CBD is increasingly used as a food supplement and in food supplement compositions, and ingredient in cosmetics, thereby generating new investments and creating employment in the cultivation and processing of hemp and hemp-derived products. Pharmaceutical products with CBD as an active ingredient have also been developed.
The European Industrial Hemp Association (EIHA) this week criticized “a few pharmaceutical companies” for leading a fight for legislation that would make CBD a prescription-only drug, on the heels of recent developments in Germany and the UK. The Association called for “urgent” action to overcome what it sees at present as “only a tenuous patchwork of CBD-regulation(s)” currently on the books.